Bg pattern

XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Xevudy 500 mg concentrate for solution for infusion

sotrovimab

This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.

Read all of this leaflet carefully before you are given this medicine.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Xevudy and what is it used for
  2. What you need to know before you are given Xevudy
  3. How Xevudy is given
  4. Possible side effects
  5. Storage of Xevudy
  6. Contents of the pack and other information

1. What is Xevudy and what is it used for

Xevudy contains the active substance sotrovimab. Sotrovimab is a monoclonal antibody, a type of protein modified to recognize a specific target on the SARS-CoV-2 virus, the virus that causes COVID-19.

Xevudy is used to treat COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kg). It targets the spike protein that the virus uses to attach to cells, preventing the virus from entering the cell and producing new viruses. By preventing the virus from multiplying in the body, Xevudy can help your body overcome the infection and prevent serious illness.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Xevudy

You must not be given Xevudy

  • if you are allergic to sotrovimab or any of the other ingredients of this medicine (listed in section 6).
  • Tell your doctorif you think this applies to you.

Warnings and precautions

Allergic reactions

Xevudy can cause allergic reactions.

  • See "Allergic reactions" in Section 4.

Infusion-related reactions

Xevudy can cause infusion-related reactions.

  • See "Infusion-related reactions" in Section 4.

Children and adolescents

Xevudy must not be given to children or adolescents under 12 years of age or weighing less than 40 kg.

Other medicines and Xevudy

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breastfeeding

If you are pregnant, think you may be pregnantor are planning to have a baby, ask your doctorfor advice before being given Xevudy. Your doctor will decide if the benefits of treatment with Xevudy outweigh the potential risks to you and your baby.

It is not knownif the components of Xevudy can pass into breast milk. If you are breastfeeding, ask your doctorfor advice before being given Xevudy.

Driving and using machines

Xevudy is not expected to affect your ability to drive or use machines.

Xevudy contains polysorbate

This medicine contains 4.8 mg of polysorbate 80 in each 500 mg dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergy.

3. How Xevudy is given

The recommended dose for adults and adolescents (12 years of age or older and weighing at least 40 kg) is:

  • 500 mg (one vial)

The medicine will be prepared in a solution and given to you by drip (infusion) into a vein by a doctor or nurse. It takes up to 30 minutes to give you the full dose of the medicine. You will be monitored during and for at least 1 hour after the treatment.

The "Instructions for healthcare professionals" below provide details for your doctor, pharmacist or nurse on how to prepare and administer the infusion of Xevudy.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

Allergic reactions to Xevudy are commonand affect up to 1 in 10 people.

Rarely, these allergic reactions can be serious (anaphylaxis), affecting up to 1 in 1,000 people (rare). If you get any of the following symptoms after being given Xevudy, you may be having an allergic reaction and should seek medical help immediately:

  • skin rash, like hives or redness of the skin
  • itching
  • swelling, sometimes of the face or mouth (angioedema)
  • increased wheezing (high-pitched sound when breathing), cough or difficulty breathing
  • sudden feeling of weakness or dizziness (which can cause loss of consciousness or falls)

Infusion-related reactions

It is commonfor infusion-related reactions to occur when receiving an infusion, affecting up to 1 in 10 people. These reactions usually develop within minutes or hours but can appear up to 24 hours after treatment or later. The following symptoms are possible. If you get any of these symptoms after being given Xevudy, you may be having an infusion-related reaction and should seek medical help immediately:

  • redness of the skin (flushing)
  • chills
  • fever
  • difficulty breathing
  • fast heart rate
  • low blood pressure

Other side effects

Uncommon (may affect up to 1 in 100 people)

  • shortness of breath (dyspnoea).

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Xevudy

Healthcare professionals are responsible for storing this medicine and disposing of any unused product correctly.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of the month shown.

Do not freeze.

Before dilution:

  • store in a refrigerator (2°C to 8°C)
  • store in the original package to protect from light.

Once diluted, this medicine should be used immediately. If immediate administration is not possible after dilution, the diluted solution can be stored at room temperature (up to 25°C) for up to 6 hours or in a refrigerator (2°C to 8°C) for up to 24 hours from the time of dilution until administration is complete.

6. Contents of the pack and other information

What Xevudy contains

  • The active substance is sotrovimab. Each vial contains 500 mg of sotrovimab in 8 ml of concentrate.
  • The other ingredients are histidine, histidine hydrochloride, sucrose, polysorbate 80 (E 433) (see section 2 "Xevudy contains polysorbate"), methionine and water for injections.

Appearance and pack

Xevudy is a clear, colourless or yellow to brown liquid presented in a single-use glass vial with a rubber stopper and a removable aluminium seal. Each pack contains one vial.

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

D24 YK11

Ireland

Manufacturer

GlaxoSmithKline Manufacturing S.p.A.

Strada Provinciale Asolana, 90,

43056 San Polo di Torrile, Parma

Italy

You can request more information about this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tél/Tel: + 32 (0) 10 85 52 00

Lietuva

GlaxoSmithKline Trading Services Limited

Tel: + 370 80000334

Text in Bulgarian language with contact information of GlaxoSmithKline Trading Services Limited and phone number

Luxembourg/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Belgique/Belgien

Tél/Tel: + 32 (0) 10 85 52 00

Ceská republika

GlaxoSmithKline, s.r.o.

Tel: + 420 222 001 111

[email protected]

Magyarország

GlaxoSmithKline Trading Services Limited.

Tel: + 36 80088309

Danmark

GlaxoSmithKline Pharma A/S

Tlf.: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline Trading Services Limited.

Tel: + 356 80065004

Deutschland

GlaxoSmithKline GmbH & Co. KG

Tel.: + 49 (0)89 36044 8701

[email protected]

Nederland

GlaxoSmithKline BV

Tel: + 31 (0)33 2081100

Eesti

GlaxoSmithKline Trading Services Limited.

Tel: + 372 8002640

Norge

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Ελλάδα

GlaxoSmithKline Μονοπρ?σωπη A.E.B.E.

Τηλ: + 30 210 68 82 100

Österreich

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

[email protected]

España

GlaxoSmithKline, S.A.

Tel: + 34 900 202 700

[email protected]

Polska

GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000

France

Laboratoire GlaxoSmithKline

Tél: + 33 (0)1 39 17 84 44

[email protected]

Portugal

GlaxoSmithKline – Produtos Farmacêuticos, Lda.

Tel: + 351 21 412 95 00

[email protected]

Hrvatska

GlaxoSmithKline Trading Services Limited

Tel: +385 800787089

România

GlaxoSmithKline Trading Services Limited

Tel: + 40800672524

Ireland

GlaxoSmithKline (Ireland) Limited

Tel: + 353 (0)1 4955000

Slovenija

GlaxoSmithKline Trading Services Limited

Tel: + 386 80688869

Ísland

Vistor ehf.

Sími: + 354 535 7000

Slovenská republika

GlaxoSmithKline Trading Services Limited

Tel: + 421 800500589

Italia

GlaxoSmithKline S.p.A.

Tel: + 39 (0)45 7741111

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30

Κ?προς

GlaxoSmithKline Trading Services Limited

Τηλ: + 357 80070017

Sverige

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvija

GlaxoSmithKline Trading Services Limited

Tel: + 371 80205045

Date of last revision of this leaflet

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu, and on the Spanish Agency of Medicines and Health Products (AEMPS) web site (http://www.aemps.gob.es/).

-------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals.

For more information, see the Summary of Product Characteristics.

Treatment should be prepared by a qualified healthcare professional using aseptic technique.

Traceability

In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.

Preparation of the dilution

  1. Remove a vial of sotrovimab from the refrigerator (2°C to 8°C). Allow the vial to reach room temperature, protected from light, for approximately 15 minutes.
  2. Visually inspect the vial to ensure it is free from particles and that there is no visible damage to the vial. If the vial is identified as unusable, discard it and restart preparation with a new vial.
  3. Gently rotate the vial in circles several times before use without creating air bubbles. Do not shake or vigorously agitate the vial.

Dilution instructions

  1. Withdraw and discard 8 ml from a 50 ml or 100 ml infusion bag containing 9 mg/ml (0.9%) sodium chloride solution for infusion or 5% glucose solution for infusion.
  2. Withdraw 8 ml of sotrovimab from the vial.
  3. Inject the 8 ml of sotrovimab into the infusion bag through the septum.
  4. Discard any unused solution remaining in the vial. The vial is for single use only and should only be used for one patient.
  5. Before infusion, gently move the infusion bag back and forth 3 to 5 times. Do not invert the infusion bag. Avoid the formation of air bubbles.

The diluted sotrovimab solution should be used immediately. If immediate administration is not possible after dilution, the diluted solution can be stored at room temperature (up to 25°C) for up to 6 hours or in a refrigerator (2°C to 8°C) for up to 24 hours from the time of dilution until administration is complete.

Administration instructions

  1. Connect an infusion set to the infusion bag using a standard diameter tube. It is recommended to administer the dosing solution intravenously with an in-line filter of 0.2 μm.
  2. Prepare the infusion set.
  3. Administer as an intravenous infusion over 15 minutes (when using a 50 ml infusion bag) or 30 minutes (when using a 100 ml infusion bag) at room temperature.

Disposal

Disposal of unused medicinal product and all materials that have come into contact with it should be done in accordance with local regulations.

Online doctors for XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION

Discuss questions about XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (71)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate

Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques. For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance. Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults. In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions. Patients commonly seek his care for: 

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION?
XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION?
The active ingredient in XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION is sotrovimab. This information helps identify medicines with the same composition but different brand names.
Who manufactures XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION?
XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION is manufactured by Glaxosmithkline Trading Services Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to XEVUDY 500 MG CONCENTRATE FOR INFUSION SOLUTION?
Other medicines with the same active substance (sotrovimab) include BEYFORTUS 100 mg injectable solution in pre-filled syringe, BEYFORTUS 50 mg Injectable Solution in Pre-filled Syringe, EVUSHELD 150 MG +150 MG INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media